Skip to content
10-Q

Quarterly Report

Aquestive Therapeutics, Inc. AQST

0001398733-26-000030

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 125.45M sh
Shares Diluted Q1 2026 · Mar 31, 2026 122.61M sh
Shares Diluted Q1 2026 · Mar 31, 2025 95.5M sh
Capex Q1 2026 · Mar 31, 2026 $52K
Capex Q1 2026 · Mar 31, 2025 $135K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$14.81M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$23.4M
Long Term Debt Q1 2026 · Mar 31, 2026 $45M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $110.73M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $121.17M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$34.05M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$33.66M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$60.93M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$60.16M
Current Liabilities Q1 2026 · Mar 31, 2026 $31.75M
Current Liabilities Q1 2026 · Dec 31, 2025 $47.61M
Total Liabilities Q1 2026 · Mar 31, 2026 $175.18M
Total Liabilities Q1 2026 · Dec 31, 2025 $194.09M
Current Assets Q1 2026 · Mar 31, 2026 $130.18M
Current Assets Q1 2026 · Dec 31, 2025 $149.27M
Total Assets Q1 2026 · Mar 31, 2026 $141.13M
Total Assets Q1 2026 · Dec 31, 2025 $160.43M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.07
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.24
Eps Basic Q1 2026 · Mar 31, 2026 −$0.07
Eps Basic Q1 2026 · Mar 31, 2025 −$0.24
Sga Expense Q1 2026 · Mar 31, 2026 $10.98M
Sga Expense Q1 2026 · Mar 31, 2025 $19.07M
Rd Expense Q1 2026 · Mar 31, 2026 $4.2M
Rd Expense Q1 2026 · Mar 31, 2025 $5.36M
Net Income Q1 2026 · Mar 31, 2026 −$8.06M
Net Income Q1 2026 · Mar 31, 2025 −$22.93M
Operating Income Q1 2026 · Mar 31, 2026 −$4.2M
Operating Income Q1 2026 · Mar 31, 2025 −$19.37M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $3.47M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $3.65M
Revenue Q1 2026 · Mar 31, 2026 $14.45M
Revenue Q1 2026 · Mar 31, 2025 $8.72M